Literature DB >> 16609011

Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.

Noriko Koyama1, Steffen Koschmieder, Sandhya Tyagi, Ignacio Portero-Robles, Jörg Chromic, Silke Myloch, Heike Nürnberger, Tanja Rossmanith, Wolf-Karsten Hofmann, Dieter Hoelzer, Oliver Gerhard Ottmann.   

Abstract

Protein tyrosine phosphatase 1B (PTP1B) is a negative regulator of BCR-ABL-mediated transformation in vitro and in vivo. To investigate whether PTP1B modulates the biological effects of the abl kinase inhibitor STI571 in BCR-ABL-positive cells, we transfected Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia cell-derived K562 cells with either wild-type PTP1B (K562/PTP1B), a substrate-trapping dominant-negative mutant PTP1B (K562/D181A), or empty vector (K562/mock). Cells were cultured with or without STI571 and analyzed for its effects on proliferation, differentiation, and apoptosis. In both K562/mock and K562/PTP1B cells, 0.25 to 1 mumol/L STI571 induced dose-dependent growth arrest and apoptosis, as measured by a decrease of cell proliferation and an increase of Annexin V-positive cells and/or of cells in the sub-G(1) apoptotic phase. Western blot analysis showed increased protein levels of activated caspase-3 and caspase-8 and induction of poly(ADP-ribose) polymerase cleavage. Low concentrations of STI571 promoted erythroid differentiation of these cells. Conversely, K562/D181A cells displayed significantly lower PTP1B-specific tyrosine phosphatase activity and were significantly less sensitive to STI571-induced growth arrest, apoptosis, and erythroid differentiation. Pharmacologic inhibition of PTP1B activity in wild-type K562 cells, using bis(N,N-dimethylhydroxamido)hydroxooxovanadate, attenuated STI571-induced apoptosis. Lastly, comparison of the STI571-sensitive Ph+ acute lymphoblastic leukemia cell line SupB15 with a STI571-resistant subline revealed significantly decreased PTP1B activity and enhanced BCR-ABL phosphorylation in the STI571-resistant SupB15 cells. In conclusion, functional PTP1B is involved in STI571-induced growth and cell cycle arrest, apoptosis, and differentiation, and attenuation of PTP1B function may contribute to resistance towards STI571.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16609011     DOI: 10.1158/1078-0432.CCR-04-2392

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  9 in total

1.  Protein tyrosine phosphatase interacting protein 51 (PTPIP51) mRNA expression and localization and its in vitro interacting partner protein tyrosine phosphatase 1B (PTP1B) in human placenta of the first, second, and third trimester.

Authors:  Albrecht Stenzinger; David Märker; Philipp Koch; Jens Hoffmann; Nelli Baal; Klaus Steger; Monika Wimmer
Journal:  J Histochem Cytochem       Date:  2008-10-14       Impact factor: 2.479

2.  Highly parallel identification of essential genes in cancer cells.

Authors:  Biao Luo; Hiu Wing Cheung; Aravind Subramanian; Tanaz Sharifnia; Michael Okamoto; Xiaoping Yang; Greg Hinkle; Jesse S Boehm; Rameen Beroukhim; Barbara A Weir; Craig Mermel; David A Barbie; Tarif Awad; Xiaochuan Zhou; Tuyen Nguyen; Bruno Piqani; Cheng Li; Todd R Golub; Matthew Meyerson; Nir Hacohen; William C Hahn; Eric S Lander; David M Sabatini; David E Root
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-17       Impact factor: 11.205

3.  Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.

Authors:  Jay Gunawardana; Fong Chun Chan; Adèle Telenius; Bruce Woolcock; Robert Kridel; King L Tan; Susana Ben-Neriah; Anja Mottok; Raymond S Lim; Merrill Boyle; Sanja Rogic; Lisa M Rimsza; Chrystelle Guiter; Karen Leroy; Philippe Gaulard; Corinne Haioun; Marco A Marra; Kerry J Savage; Joseph M Connors; Sohrab P Shah; Randy D Gascoyne; Christian Steidl
Journal:  Nat Genet       Date:  2014-02-16       Impact factor: 38.330

4.  The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.

Authors:  Patricia Mambou Gwanmesia; Annette Romanski; Kerstin Schwarz; Biserka Bacic; Martin Ruthardt; Oliver G Ottmann
Journal:  BMC Cancer       Date:  2009-02-13       Impact factor: 4.430

5.  PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.

Authors:  Julia Drube; Thomas Ernst; Markus Pfirrmann; Benadict Vincent Albert; Sebastian Drube; Daniela Reich; Anne Kresinsky; Kathrin Halfter; Claudio Sorio; Christian Fabisch; Andreas Hochhaus; Frank-D Böhmer
Journal:  Oncotarget       Date:  2018-01-15

6.  The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis.

Authors:  Afsar A Mian; Ines Baumann; Marcus Liebermann; Florian Grebien; Giulio Superti-Furga; Martin Ruthardt; Oliver G Ottmann; Oliver Hantschel
Journal:  Leukemia       Date:  2019-04-08       Impact factor: 11.528

7.  Sequential Cdk1 and Plk1 phosphorylation of protein tyrosine phosphatase 1B promotes mitotic cell death.

Authors:  D S O'Donovan; S MacFhearraigh; J Whitfield; L B Swigart; G I Evan; M M Mc Gee
Journal:  Cell Death Dis       Date:  2013-01-24       Impact factor: 8.469

8.  CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma.

Authors:  Yichuan Chen; Jingqun Tang; Ting Lu; Fang Liu
Journal:  Thorac Cancer       Date:  2020-05-12       Impact factor: 3.500

Review 9.  Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia.

Authors:  Christian Boni; Claudio Sorio
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.